Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

US · MD National Institutes of Health (NIH) grant open #PAR-25-059

Response due Oct 20, 2027 · 00:00 UTC

Summary

The NIH IGNITE program funds early-stage translational research focused on assay development and the identification of neurotherapeutic agents. The R61/R33 phased award mechanism supports milestone-driven projects that advance drug discovery pipelines for neurological conditions. Clinical trials are explicitly excluded from this funding opportunity. The program is designed to bridge basic science findings toward viable therapeutic candidates through structured translational milestones.

What they want

Technical requirements

Clinical trials are not allowed under this funding opportunity
R61/R33 phased award mechanism required
Milestone-driven research design required
Focus must be on assay development and/or neurotherapeutic agent identification

How they evaluate

Submission: Electronic submission via Grants.gov federal grants portal (PAR-25-059)

Risks & flags

No dollar value or award ceiling disclosed in the available text — budget constraints unknown
Extremely long open window (Oct 2024 – Oct 2027) with rolling deadlines may obscure actual competition cycles and review timelines

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Innovation Grants to Nurture Initial Trans…

Due Oct 20

Onboard ↗